# OMNIVORE (NCT03203473)

> Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03203473
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Toni Choueiri, MD
- Conditions: Renal Cancer
- Interventions: Ipilimumab; Nivolumab
- Enrollment: 85
- Primary outcome: Percentage of Subjects With Persistent Partial Response (PR) or Complete Response (CR) at 1 Year Since Nivolumab Discontinuation (Arm A Only)
- Primary outcome: Percentage of Subjects With Stable or Progressive Disease (SD/PD) to Nivolumab Induction That Convert to Complete or Partial Response (CR/PR) Upon the Addition of Ipilimumab to Nivolumab (Arm B Only)

## Indexed commentary on OMNIVORE so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 15
- Podcasts: 4
- YouTube: 3
- X videos: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=omnivore-nct03203473

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03203473", "email": "<work email>"}; the inbox owner confirms by the emailed link.